Ensho Therapeutics has emerged with an inflammatory disease therapy portfolio from Eisai’s GI subsidiary EA Pharma, including a phase 2-ready clinical program in ulcerative colitis (UC).
CHUO-KU, TOKYO and MORRIS PLAINS, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- EA Pharma Co., Ltd. (President, Hidenori Yabune; “EA Pharma”) and Ensho Therapeutics, Inc. (Founder, President and Chief...